Galangin suppresses hepatocellular carcinoma cell proliferation by reversing the Warburg effect - 14/11/17
pages | 6 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Galangin enhances aerobic metabolism to inhibite the glycolysis of HCC cells. |
• | Galangin up-regulates glycolytic rate-limiting enzyme pyruvate kinase activity. |
• | Galangin inhibits HCC proliferation by reversing the Warburg effect. |
Abstract |
Hepatocellular carcinoma (HCC) is the sixth most common cancer. The Warburg effect is an important way by which HCC adapts to a hypoxic environment. The aim of the present study was to determine whether and how galangin reverses the Warburg effect in HCC cells. We treated three HCC cell lines, HepG2, Hep3B and PLC/PRF/5 with galangin for 24h, respectively. Cell proliferation was measured with MTT assay. Glucose uptake, lactate production and the oxygen consumption were measured. Pyruvate kinase activities were detected by measuring the consumption of NADH, and glycolytic pathway-related proteins were measured by Western blotting. The results showed that galangin suppressed proliferation of HCC cells, decreased glucose absorption and lactate production of HCC. In addition, galangin also gave rise to increased oxygen consumption in all three HCC cell lines. After treatment with galangin, the activity of pyruvate kinase was up-regulated and the expression levels of glycolytic pathway-related proteins were changed. These results suggest that galangin suppresses the Warburg effect in HCC cells, indicating that galangin might be a potential therapeutic agent for HCC.
Le texte complet de cet article est disponible en PDF.Keywords : Galangin, Hepatocellular carcinoma cells, Warburg effect, Glycolysis, Proliferation
Plan
Vol 95
P. 1295-1300 - novembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?